Sequenom, Inc.  

(Public, NASDAQ:SQNM)   Watch this stock  
Find more results for SQNM
+0.01 (0.56%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.75 - 1.81
52 week 1.53 - 4.80
Open 1.76
Vol / Avg. 168,166.00/875,803.00
Mkt cap 209.87M
P/E 16.55
Div/yield     -
EPS 0.11
Shares 118.57M
Beta 0.75
Inst. own 58%
Dec 1, 2015
Sequenom Inc at Piper Jaffray Healthcare Conference - 8:00AM EST - Add to calendar
Nov 4, 2015
Q3 2015 Sequenom Inc Earnings Call
Nov 4, 2015
Q3 2015 Sequenom Inc Earnings Release
Sep 28, 2015
Sequenom Inc Investor and Analyst Day
Sep 16, 2015
Sequenom Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -31.58% -9.48%
Operating margin -24.35% -9.04%
EBITD margin - -14.79%
Return on average assets -28.55% -9.40%
Return on average equity - -
Employees 448 -
CDP Score - -


3595 John Hopkins Ct
SAN DIEGO, CA 92121-1121
United States - Map
+1-858-2029000 (Phone)
+1-858-2029001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Company's diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories' test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.

Officers and directors

Kenneth F. Buechler Ph.D. Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Dirk van den Boom Ph.D. Interim President, Chief Executive Officer, Chief Scientific and Strategy Officer, Director
Age: 46
Bio & Compensation  - Reuters
Carolyn D. Beaver CPA Chief Financial Officer, Senior Vice President
Age: 57
Bio & Compensation  - Reuters
Jeffrey D. Linton J.D. Senior Vice President, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Daniel S. Grosu Senior Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
Robin G Weiner Senior Vice President, Corporate Governance and Regulatory Affairs
Age: 59
Bio & Compensation  - Reuters
Richard A. Lerner M.D. Lead Independent Director
Age: 76
Bio & Compensation  - Reuters
Myla P. Lai-Goldman M.D. Director
Age: 57
Bio & Compensation  - Reuters
Ronald M. Lindsay Ph.D. Director
Age: 67
Bio & Compensation  - Reuters
Catherine J. Mackey Ph.D. Director
Age: 59
Bio & Compensation  - Reuters